CO6551731A2 - Composiciòn de combinaciòn que comprende como ingrediente activo l- carnitina o propionil l- carnitina, para la prevenciòn o tratamiento de insuficienca venosa crònica - Google Patents

Composiciòn de combinaciòn que comprende como ingrediente activo l- carnitina o propionil l- carnitina, para la prevenciòn o tratamiento de insuficienca venosa crònica

Info

Publication number
CO6551731A2
CO6551731A2 CO12103267A CO12103267A CO6551731A2 CO 6551731 A2 CO6551731 A2 CO 6551731A2 CO 12103267 A CO12103267 A CO 12103267A CO 12103267 A CO12103267 A CO 12103267A CO 6551731 A2 CO6551731 A2 CO 6551731A2
Authority
CO
Colombia
Prior art keywords
carnitine
prevention
treatment
propionil
critical
Prior art date
Application number
CO12103267A
Other languages
English (en)
Inventor
Mohamed Ashraf Virmani
Aleardo Koverech
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of CO6551731A2 publication Critical patent/CO6551731A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

Se describe una composición de combinación que comprende como ingredientes activos L-carnitina o propioriil L-carnitina, troxerutina, diosmina y hesperidina, útil para la prevención y/o tratamiento de enfermedades venosas crónicas.
CO12103267A 2010-02-02 2012-06-20 Composiciòn de combinaciòn que comprende como ingrediente activo l- carnitina o propionil l- carnitina, para la prevenciòn o tratamiento de insuficienca venosa crònica CO6551731A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10152363A EP2353596A1 (en) 2010-02-02 2010-02-02 Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency
US32253210P 2010-04-09 2010-04-09

Publications (1)

Publication Number Publication Date
CO6551731A2 true CO6551731A2 (es) 2012-10-31

Family

ID=41820403

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12103267A CO6551731A2 (es) 2010-02-02 2012-06-20 Composiciòn de combinaciòn que comprende como ingrediente activo l- carnitina o propionil l- carnitina, para la prevenciòn o tratamiento de insuficienca venosa crònica

Country Status (20)

Country Link
US (3) US20110189152A1 (es)
EP (2) EP2353596A1 (es)
CN (1) CN102791263B (es)
AU (1) AU2011212153B2 (es)
BR (1) BR112012019351A2 (es)
CO (1) CO6551731A2 (es)
DK (1) DK2531189T3 (es)
EA (1) EA021107B1 (es)
ES (1) ES2487647T3 (es)
IL (1) IL221273A (es)
MX (1) MX2012008890A (es)
NZ (1) NZ600695A (es)
PE (1) PE20121700A1 (es)
PL (1) PL2531189T3 (es)
PT (1) PT2531189E (es)
RS (1) RS53515B1 (es)
SG (1) SG182323A1 (es)
SI (1) SI2531189T1 (es)
UA (1) UA107687C2 (es)
WO (1) WO2011095882A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2999934B1 (fr) * 2012-12-21 2015-02-20 Servier Lab Composition pharmaceutique sous la forme d'une suspension orale comprenant une fraction flavonoique et de la gomme xanthane
EA028998B1 (ru) * 2013-12-05 2018-01-31 Альфасигма С.П.А. Композиция, применимая для активации женской репродуктивной способности
FR3019820B1 (fr) * 2014-04-15 2017-07-21 Peter Weyts Composes de type flavonoides pour leur utilisation dans le traitement d'une pathologie du pied d'un mammifere ongule-composition pharmaceutique associee
CN104605451A (zh) * 2015-01-31 2015-05-13 丁年生 一种防止毛细血管出血的玫瑰花饮料及其制备方法
RU2704976C2 (ru) * 2017-05-10 2019-11-01 Общество с ограниченной ответственностью "Трейдсервис" Флеботропная комбинированная фармацевтическая композиция
RU2705794C1 (ru) * 2018-09-26 2019-11-12 Общество с ограниченной ответственностью "Трейдсервис" Комбинированная мягкая лекарственная форма для лечения геморроидальных заболеваний
RU2689409C1 (ru) * 2018-11-21 2019-05-28 Общество с ограниченной ответственностью "Трейдсервис" Комбинированная мягкая лекарственная форма диосмина и троксерутина
IT202000003122A1 (it) * 2020-02-17 2021-08-17 Apharm Srl Associazione di principi attivi e loro uso nel trattamento e/o nella prevenzione della insufficienza venosa
HUP2100299A1 (hu) 2021-08-19 2023-02-28 Keri Pharma Hungary Kft Új gyógyászati kombináció alkalmazása krónikus vénás elégtelenség kezelésére

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903558C2 (de) 1978-02-03 1994-09-01 Sigma Tau Ind Farmaceuti Verwendung von L-Carnitin
IT1156852B (it) 1978-07-10 1987-02-04 Sigma Tau Ind Farmaceuti Procedimento industriale per la preparazione del d'canforato della l carnitinammide e del d canforato della d carnitinammide e sue applicazioni
IT1206954B (it) 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT1142934B (it) * 1981-11-06 1986-10-15 Sigma Tau Ind Farmaceuti Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene
CH662505A5 (it) * 1985-04-30 1987-10-15 Seuref Ag Composizioni farmaceutiche ad azione protettiva vascolare.
JP2669146B2 (ja) 1990-11-26 1997-10-27 富士電機株式会社 半導体素子の保護用ヒューズ
FR2710844B1 (fr) * 1993-10-07 1995-12-29 Bidel Christian Georges Composition pour le traitement ou la prévention de l'herpès.
ES2141463T3 (es) 1996-03-04 2000-03-16 Sigma Tau Ind Farmaceuti Medicamento conteniendo un derivado de la carnitina para el tratamiento de la arteriosclerosis obliterans.
US5949786A (en) * 1996-08-15 1999-09-07 3Com Corporation Stochastic circuit identification in a multi-protocol network switch
IT1302863B1 (it) * 1998-11-13 2000-10-10 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante e preventiva di alterazionitrombotiche e aterosclerotiche comprendente una carnitina ed un
ITRM20020055A1 (it) * 2002-02-04 2003-08-04 Aldo Fassi Sali metallici di carnitine, integratori dietetici/nutritivi che li contengono e kit dietetici per contrastare disturbi sessuali in soggetti
DE10240923A1 (de) * 2002-09-02 2004-03-04 Merck Patent Gmbh Flavonoid-Derivate zur Ekzem-Behandlung
ITRM20030178A1 (it) 2003-04-17 2004-10-18 Sigma Tau Ind Farmaceuti Uso della l-carnitina per il trattamento di patologie cardiovascolari.
AT501682A1 (de) * 2005-01-14 2006-10-15 Hermine Dr Engl Verfahren zur herstellung einer wirkstoffmischung
US20070087975A1 (en) 2005-10-17 2007-04-19 Sigma-Tau Industrie Farmaceutiche Riunite Spa Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients
MX2007011002A (es) * 2007-09-07 2009-03-09 World Trade Imp Export Wtie Ag Composicion farmaceutica que comprende la combinacion de diversos agentes venotonicos y vasoprotectores para el tratamiento de la insuficiencia venosa cronica.

Also Published As

Publication number Publication date
UA107687C2 (ru) 2015-02-10
EA021107B1 (ru) 2015-04-30
BR112012019351A2 (pt) 2017-06-27
US20110189152A1 (en) 2011-08-04
IL221273A0 (en) 2012-10-31
US20130005670A1 (en) 2013-01-03
EP2531189A1 (en) 2012-12-12
DK2531189T3 (da) 2014-09-01
EA201200786A1 (ru) 2013-01-30
WO2011095882A1 (en) 2011-08-11
MX2012008890A (es) 2012-08-31
ES2487647T3 (es) 2014-08-22
AU2011212153A1 (en) 2012-07-05
SI2531189T1 (sl) 2014-09-30
EP2353596A1 (en) 2011-08-10
CN102791263B (zh) 2016-10-12
RS53515B1 (en) 2015-02-27
PL2531189T3 (pl) 2014-10-31
US20140018310A1 (en) 2014-01-16
CN102791263A (zh) 2012-11-21
AU2011212153B2 (en) 2016-08-04
PT2531189E (pt) 2014-08-25
PE20121700A1 (es) 2012-12-22
NZ600695A (en) 2014-03-28
EP2531189B1 (en) 2014-06-11
US9457037B2 (en) 2016-10-04
IL221273A (en) 2015-07-30
WO2011095882A8 (en) 2012-08-02
SG182323A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
CO6551731A2 (es) Composiciòn de combinaciòn que comprende como ingrediente activo l- carnitina o propionil l- carnitina, para la prevenciòn o tratamiento de insuficienca venosa crònica
GT201200276A (es) Combinaciones de compuestos activos
CL2013001436A1 (es) Composicion que comprende al menos una n-acetil-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado; y su uso para la prevencion y/o tratamiento de las condiciones de la piel y enfermedades de la piel.
CO6741228A2 (es) Inhibidores de la neprilisina
CL2014000601A1 (es) Composición tópica veterinaria que comprende al menos un agente activo derivado de isoxazolina; y uso de la composición para el tratamiento o prevención de una infestación o infección por parásitos en un animal.
BR112013013402A2 (pt) combinações de ingredientes ativos que compreendem piridiletilbenzamidas e outros ingredientes ativos
CL2014000470A1 (es) Compuestos derivados del acido 2-oxo-piridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para tratar o mejorar una infeccion bacteriana.
ECSP10010494A (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
UA108887C2 (xx) Кристалічна форма бензил-бензольного інгібітора sglt2
DOP2016000253A (es) Nuevos compuestos
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CO6870038A2 (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
DOP2010000331A (es) Formulacion de medicamento solida con liberacion retardada
CR20110190A (es) Agente rodenticida sinérgico
WO2013185764A3 (en) Pharmaceutical compositions for combination therapy
CL2014003276A1 (es) Uso de polisacárido de poli n-acetil glucosamina (pnag) para prevenir o tratar una infección por un patógeno positivo a pnag sin ica/pga; composición farmacéutica que comprende dicho polisacárido; y uso de anticuerpo contra pnag para tratar infección por ciertos patógenos.
BR112016005417A8 (pt) "compostos derivados de desoxinojirimicina, composição farmacêutica e seus usos"
DOP2016000007A (es) Pirazolpiridinas sustituidas
AR077703A1 (es) Composicion de control de plagas
CL2015000091A1 (es) Apósitos con una liberación prolongada de agentes activos.
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico
BR112012007798A2 (pt) microcápsulas estáveis e composição para aplicação tópica e método para a preparação de microcápsulas
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
AR094224A1 (es) Composicion farmaceutica en forma de una suspension oral
BR112015002984A2 (pt) composição, vacina para proteger um animal contra uma infecção com bactérias leptospira, e, uso de ácido cítrico.

Legal Events

Date Code Title Description
FC Application refused